Biology of Blood and Marrow Transplantation
Volume 12, Issue 1 , Pages 102-110 , January 2006

Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-Leukemia Reaction? A Prospective Phase II Study

Presented in part at the Annual Meeting of the American Society of Hematology, San Diego, CA, December 6-9, 2003

  • Yves Chalandon

      Affiliations

    • Hematology Service, Department of Internal Medicine University Hospital, Geneva, Switzerland
    • Corresponding Author InformationCorrespondence and reprint requests: Yves Chalandon, MD, Hematology Service, University Hospital of Geneva, 24 rue Micheli-du-Crest, 1211 Geneva 14, Switzerland.
    • ,
  • Eddy Roosnek

      Affiliations

    • Immunology and Allergology Service, Department of Internal Medicine University Hospital, Geneva, Switzerland
    • ,
  • Bernadette Mermillod

      Affiliations

    • Medical Informatics Service, Department of Internal Medicine University Hospital, Geneva, Switzerland
    • ,
  • Laurent Waelchli

      Affiliations

    • Oncology Service, Department of Internal Medicine University Hospital, Geneva, Switzerland
    • ,
  • Claudine Helg

      Affiliations

    • Hematology Service, Department of Internal Medicine University Hospital, Geneva, Switzerland
    • ,
  • Bernard Chapuis

      Affiliations

    • Hematology Service, Department of Internal Medicine University Hospital, Geneva, Switzerland

Received 29 June 2005 ,Accepted 16 September 2005.

  • Image Result

    A, Incidence of aGVHD grade I and II (○) and grade II only (•). B, Incidence of cGVHD (limited and extensive) after allogeneic PBSC transplantation partially T-cell depleted in vitro with Campath-1H.

    A, Incidence of aGVHD grade I and II (○) and grade II only (•). B, Incidence of cGVHD (limited and extensive) after allogeneic PBSC transplantation partially T-cell depleted in vitro with Campath-1H.

  • Image Result

    OS (•) and TRM (○) after allogeneic PBSC transplantation partially T-cell depleted in vitro with Campath-1H.

    OS (•) and TRM (○) after allogeneic PBSC transplantation partially T-cell depleted in vitro with Campath-1H.

  • Image Result

    EFS (A) and incidence of relapse (B) after allogeneic PBSC transplantation partially T-cell depleted in vitro with Campath-1H.

    EFS (A) and incidence of relapse (B) after allogeneic PBSC transplantation partially T-cell depleted in vitro with Campath-1H.

  • Image Result

    OS after allogeneic PBSC transplantation partially T-cell depleted in vitro with Campath-1H in patients with CML (○) and in patients with other diseases (•).

    OS after allogeneic PBSC transplantation partially T-cell depleted in vitro with Campath-1H in patients with CML (○) and in patients with other diseases (•).

  • Image Result

    DFS after allogeneic PBSC transplantation partially T-cell depleted in vitro with Campath-1H.

    DFS after allogeneic PBSC transplantation partially T-cell depleted in vitro with Campath-1H.

PII: S1083-8791(05)00674-9

doi: 10.1016/j.bbmt.2005.09.010

Biology of Blood and Marrow Transplantation
Volume 12, Issue 1 , Pages 102-110 , January 2006

Article Tools

* Image Usage & Resolution